Please assess the completion status of the following clinical trial:

Trial Title: E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heterosexually active female at risk for pregnancy and requesting contraception.~* Negative serum pregnancy test at subject screening.~* Willing to use the investigational product as the primary method of contraception for 13 consecutive cycles.~* Good physical and mental health on the basis of medical, surgical and gynecological history, physical examination, gynecological examination, clinical laboratory, and vital signs.~* Body mass index (BMI) below or equal to (≤) 35.0 kg/m2.~* Able to fulfill the requirements of the protocol and have indicated a willingness to participate in the study by providing written informed consent.~* Willing and able to complete the diaries and questionnaires.~Exclusion Criteria:~* Known hypersensitivity to any of the investigational product ingredients.~* Smoking if ≥ 35 years old, at screening.~* Any condition associated with decrease fertility.~* Dyslipoproteinemia requiring active treatment with antilipidemic agent.~* Diabetes mellitus with vascular involvement (nephropathy, retinopathy, neuropathy, other) or diabetes mellitus of more than 20-year duration.~* Arterial hypertension.~* Any condition associated with an increased risk of venous thromboembolism and/or arterial thromboembolism.~* Any condition associated with abnormal uterine/vaginal bleeding.~* Abnormal Pap test based on current international recommendations.~* Presence of an undiagnosed breast mass.~* Current symptomatic gallbladder disease.~* History of combined oral contraceptive (COC) related cholestasis.~* Presence or history of severe hepatic disease.~* Presence or history of pancreatitis if associated with hypertriglyceridemia.~* Porphyria.~* Presence or history of hepatocellular adenoma or malignant liver tumors.~* Renal impairment.~* Hyperkaliemia or presence of conditions that predispose to hyperkaliemia.~* Presence or history of hormone-related malignancy.~* History of non-hormone-related malignancy within 5 years before screening. Subjects with a non-melanoma skin cancer are allowed in the study.~* History of alcohol or drug abuse (including laxatives) within 12 months prior to screening.~* Use of drugs potentially triggering interactions with COCs.~* Any condition that could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the investigational product.~* Uncontrolled thyroid disorders.~* Participation in another investigational drug clinical study within 1 month (30 days) or have received an investigational drug within the last 3 months (90 days) prior to study entry. Subjects who participated in an oral contraceptive clinical study, using FDA/European (EU) approved active ingredients, may be enrolled 2 months (60 days) after completing the preceding study.~* Sponsor, Contract Research Organization (CRO) or Investigator's site personnel directly affiliated with this study.~* Is judged by the Investigator to be unsuitable for any reason.

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 15 mg E4/3 mg DRSP (Type: EXPERIMENTAL): 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combined oral contraceptive

Based on this trial design, predict the completion outcome and termination type (if applicable).